Mauricio Cabrera

List of Publications by Year
in descending order

30 papers	903 citations	516710 16 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	1417 citing authors

#	Article	IF	Citations
1	Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay. Bioorganic Chemistry, 2020, 94, 103372.	4.1	2
2	Novel and selective inactivators of Triosephosphate isomerase with anti-trematode activity. Scientific Reports, 2020, 10, 2587.	3.3	12
3	Cathepsin L Inhibitors with Activity against the Liver Fluke Identified From a Focus Library of Quinoxaline 1,4-di-N-Oxide Derivatives. Molecules, 2019, 24, 2348.	3.8	7
4	Discovery of Potent EGFR Inhibitors through the Incorporation of a 3Dâ€Aromaticâ€Boronâ€Richâ€Cluster into the 4â€Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment. Chemistry - A European Journal, 2018, 24, 3122-3126.	3.3	54
5	Novel and Selective Rhipicephalus microplus Triosephosphate Isomerase Inhibitors with Acaricidal Activity. Veterinary Sciences, 2018, 5, 74.	1.7	13
6	Smallâ€Molecule Kinaseâ€Inhibitorsâ€Loaded Boron Cluster as Hybrid Agents for Gliomaâ€Cellâ€Targeting Therapy. Chemistry - A European Journal, 2017, 23, 9233-9238.	3.3	50
7	Frontispiece: Smallâ€Molecule Kinaseâ€Inhibitorsâ€Loaded Boron Cluster as Hybrid Agents for Gliomaâ€Cellâ€Targeting Therapy. Chemistry - A European Journal, 2017, 23, .	3.3	0
8	New hybrid bromopyridine-chalcones as in vivo phase II enzyme inducers: potential chemopreventive agents. MedChemComm, 2016, 7, 2395-2409.	3.4	8
9	In vivo phase II-enzymes inducers, as potential chemopreventive agents, based on the chalcone and furoxan skeletons. Bioorganic and Medicinal Chemistry, 2016, 24, 1665-1674.	3.0	18
10	Identification of Chalcones as Fasciola hepatica Cathepsin L Inhibitors Using a Comprehensive Experimental and Computational Approach. PLoS Neglected Tropical Diseases, 2016, 10, e0004834.	3.0	23
11	3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action Studies. Molecules, 2015, 20, 14595-14610.	3.8	11
12	Searching phase II enzymes inducers, from Michael acceptor-[1,2]dithiolethione hybrids, as cancer chemopreventive agents. Future Medicinal Chemistry, 2015, 7, 857-871.	2.3	12
13	New hits as phase II enzymes inducers from a focused library with heteroatomâ€“heteroatom and Michael-acceptor motives. Future Science OA, 2015, 1, FSO20.	1.9	4
14	A serendipitous one-step conversion of 3H-1,2-dithiole-3-thione to (E)-3-[1-(alkylthio)alkylidene]-3H-1,2-dithiole: an experimental and theoretical study. Molecular Diversity, 2014, 18, 285-294.	3.9	7
15	Mutagenicity of N-oxide Containing Heterocycles and Related Compounds: Experimental and Theoretical Studies. Current Topics in Medicinal Chemistry, 2014, 14, 1374-1387.	2.1	18
16	Biotransformation of Phenazine 5,10-Dioxides under Hypoxic Conditions as an Example of Activation of Anticancer Prodrug: An Interdisciplinary Experiment for Biochemistry or Organic Chemistry. Journal of Chemical Education, 2013, 90, 1388-1391.	2.3	4
17	Bioactive-guided Identification of Labdane Diterpenoids from Aerial Parts of Aristeguietia glutinosa as anti-Trypanosoma cruzi agents. Natural Product Communications, 2012, 7, 1934578X1200700.	0.5	2
18	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	3.0	62

#	Article	IF	Citations
19	3-Trifluoromethylquinoxaline N,Nâ€²-Dioxides as Anti-Trypanosomatid Agents. Identification of Optimal Anti-T. cruzi Agents and Mechanism of Action Studies. Journal of Medicinal Chemistry, 2011, 54, 3624-3636.	6.4	49
20	Genetic toxicology and preliminaryin vivostudies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents. Drug and Chemical Toxicology, 2011, 34, 285-293.	2.3	10
21	Novel Phenazine 5,10-Dioxides Release ^{â€¢}OH in Simulated Hypoxia and Induce Reduction of Tumour Volume In Vivo. ISRN Pharmacology, 2011, 2011, 1-11.	1.6	12
22	Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation. Bioorganic and Medicinal Chemistry, 2010, 18, 4433-4440.	3.0	24
23	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers. Bioorganic and Medicinal Chemistry, 2010, 18, 5391-5399.	3.0	27
24	Structural modifications on the phenazine N,Nâ€²-dioxide-scaffold looking for new selective hypoxic cytotoxins. European Journal of Medicinal Chemistry, 2010, 45, 5362-5369.	5.5	24
25	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. European Journal of Medicinal Chemistry, 2010, 45, 5767-5772.	5.5	47
26	Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs. Bioorganic and Medicinal Chemistry, 2009, 17, 1623-1629.	3.0	25
27	Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicology Letters, 2009, 190, 140-149.	0.8	31
28	New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. Journal of Inorganic Biochemistry, 2008, 102, 119-126.	3.5	58
29	Differential Enzymatic Reductions Governing the Differential Hypoxia-Selective Cytotoxicities of Phenazine 5,10-Dioxides. Chemical Research in Toxicology, 2008, 21, 1900-1906.	3.3	28
30	Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2007, 15, 3356-3367.	3.0	260